Cadila Healthcare is currently trading at Rs. 388.50, up by 3.20 points or 0.83% from its previous closing of Rs. 385.30 on the BSE.
The scrip opened at Rs. 395.00 and has touched a high and low of Rs. 395.05 and Rs. 385.70 respectively. So far 59994 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 411.60 on 05-Aug-2020 and a 52 week low of Rs. 206.45 on 22-Aug-2019.
Last one week high and low of the scrip stood at Rs. 409.70 and Rs. 381.60 respectively. The current market cap of the company is Rs. 39444.80 crore.
The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 17.15% and 7.78% respectively.
Zydus Cadila has launched Remdesivir under the brand name Remdac in the Indian market. Priced at Rs 2800 for a 100 mg lyophilized injection, Remdac is the most economical Remdesivir brand in India. The drug will be made available across India through the group’s strong distribution chain reaching out to Government and private hospitals treating COVID patients.
In June 2020, Zydus entered into a non-exclusive agreement with Gilead Sciences Inc., to manufacture and sell Remdesivir, the investigational drug, which has been issued an Emergency Use Authorization by the U.S. Food and Drug Administration (FDA) to treat patients suffering from severe symptoms of COVID 19. The API for the drug has been developed and manufactured at the group’s API manufacturing facilities in Gujarat.
Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1504.25 |
Dr. Reddys Lab | 6263.70 |
Cipla | 1406.25 |
Zydus Lifesciences | 948.20 |
Lupin | 1615.85 |
View more.. |